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This study investigates the immuno-
modulatory effects of polychromatic
polarized light therapy (PLT) on
human monocyte cells. While there is
some evidence demonstrating a clini-
cal effect in the treatment of certain
conditions, there is little research into
its mechanism of action. Herein, U937
monocyte cells were cultured and
exposed to PLT. The cells were then
analyzed for change in expression of
genes and cell surface markers relating to inflammation. It was noted that 6 hours
of PLT reduced the expression of the CD14, MHC I and CD11b receptors, and
increased the expression of CD86. It was also shown that PLT caused down-
regulation of the genes IL1B, CCL2, NLRP3 and NOD1, and upregulation of
NFKBIA and TLR9. These findings imply that PLT has the capacity for immuno-
modulation in human immune cells, possibly exerting an anti-inflammatory effect.
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1 | INTRODUCTION
Inflammation is a process heavily implicated in pathological
states of all kinds, from allergy and neoplasia, to infection.
Despite its central role in the pathophysiology of many
common conditions, current methods of managing inflam-
mation are fraught with problems, particularly in a chronic
setting. Treatment typically involves pharmacological inter-
ventions, many of which exert a range of unwanted effects
in addition to their therapeutic action [1]. The continuing
evolution and development of novel therapeutic approaches
to the management of inflammation is essential in order to
advance patient care. Evaluation of nonpharmacological
anti-inflammatory treatments is a key, but relatively under-
represented part of this process. A small but growing body
of evidence indicates that phototherapies such as polarized
light therapy (PLT) are a promising avenue of exploration
in this area [2, 3].
Received: 6 November 2019 Revised: 3 December 2019 Accepted: 5 December 2019
DOI: 10.1002/jbio.201960177
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2019 The Authors. Journal of Biophotonics published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
J. Biophotonics. 2020;13:e201960177. www.biophotonics-journal.org 1 of 9
https://doi.org/10.1002/jbio.201960177
The therapeutic benefits of light therapy have been
reported since the late 1960s with applications ranging from
neonatal jaundice to psoriasis and vitiligo [3, 4]. The theo-
retical basis of phototherapy involves the use of light to
induce physiological change within a target tissue [5], with
subsequent therapeutic effects. There are several types of
phototherapies differentiated by the specific physical quali-
ties of the light used, with the most common being low-
level laser therapy (LLLT) and ultraviolet (UV) therapies.
In recent years, however, it has been proposed that a broad
light spectrum covering all light colors, and polarization
are crucial elements in light therapy [6]. Polarized light
(PL) is formed by the filtering of light waves so that they
are aligned and vibrated in a single plane (Figure 1). Once
polarized, light has the ability to penetrate further into tis-
sues than its unpolarized counterpart [7].
Broad, visible spectrum PLT differs from other forms of
phototherapy as it uses a much wider range of wavelengths
than other modalities such as, LLLT or UV. Consequently,
the devices used in PLT are generally less expensive and
relatively easy to use. PLT has been suggested by advocates
and device manufacturers for use in several contexts such
as pain, wound healing, skin conditions and inflammatory
arthritis. Preliminary clinical evidence indicates efficacy in
the management of skin ulcers [8–10], burns [11–13], mus-
culoskeletal injuries [14–18] as well as surgical and non-
healing wounds [6, 19–22]. Despite this, there are little
scientific data regarding the physiological mechanisms
underlying these changes in vitro or in vivo [2]. It has
suggested that the interactions of light with the key mito-
chondrial enzyme cytochrome oxidase C are responsible
for the beneficial changes observed in LLLT [23–25]; how-
ever, little information has been documented exploring the
mechanisms of PLT.
With aging populations, in most developed economies,
and the associated increase in demands on health bud-
gets, noninvasive, nonpharmacological avenues of disease
treatment will be required to counter the inevitable bur-
den of inflammatory disease. PLT has the potential to be
an inexpensive, technically simple and safe photo-
therapeutic intervention. This study aimed to determine
whether PL induces cellular changes to the human mono-
cyte cell line, to provide insight into the possible mecha-
nisms of action underpinning its clinical use. It was
hypothesized that a decrease in the inflammatory profile
of immune cells may be part of the biological action of
PLT. Specifically, this involved the exposure of a cultured
U937 monocyte/macrophage cell line to PL, and subse-
quent assessment of cell surface markers and gene expres-
sion relating to inflammation. We showed that exposure
to PL decreases the expression of proinflammatory cell
surface markers and causes changes in gene expression
consistent with a decreased inflammatory profile.
2 | MATERIALS AND METHODS
All procedures in this study were performed in PC2 labo-
ratories at the Werribee campus of Victoria University,
and the Western Centre for Health Research and Educa-
tion (Western CHRE) at Sunshine hospital under stan-
dard laboratory conditions. All cell culture work was
done under aseptic conditions in a class II biosafety cabi-
net. Trypan blue staining was used before and after illu-
mination to ensure cell viability throughout the
experiments. No ethics was required for this research.
2.1 | Cell culture and cell differentiation
The U937 monocyte cell line was cultured in Roswell
Park Memorial Institute media, supplemented with 10%
fetal bovine serum (Interpath Services Pty. Ltd.), 1% peni-
cillin/streptomycin (Sigma-Aldrich) and 0.1% glutamine
(Sigma-Aldrich), and incubated at 37C, 5% CO2 as per
standard culture protocol. The cells were passaged to 50%
to 90% confluency and media replenished every 48 hours
until an adequate number of cells were obtained. A stock
of experimental cells (cell bank) was then created and
stored in liquid nitrogen. One vial from the cell bank was
thawed each time the experiment was repeated, to ensure
all experimental cells were at the same passage through-
out the experiments. U937 cells are promonocytic cells
and are differentiated into monocyte/macrophage cells
via the addition of vitamin D3 to the media to a final con-
centration of 100 nм for 72 hours [26].
2.2 | Polarized light exposure
The therapeutic PL source employed was using a Bioptron
MedAll PAG-960 lamp (Bioptron, Switzerland) with a
wavelength range from 400 to 3400 nm. The light source
has an average power density of 40 mW/cm2 evenly dis-
tributed across the wavelength spectrum. The entire appa-
ratus, including lamp and tripod, was housed completely
within an incubator (Figure 2). The incubator and media
temperatures were monitored to ensure there was no over-
heating of the culture due to the light exposure. This is to
ensure that observed effects stemmed from cellular inter-
actions with light, rather than a thermic effect. The light
from the lamp was projected perpendicularly onto a 5 cm
cell culture plate at a distance of 10 cm, according to man-
ufacturer's instructions, with full light coverage of the
sample. The lid of the culture dish containing the experi-
mental cells was removed, to avoid interference of the
light passing through. Control cells were kept in the same
incubator, separated by a solid, stainless steel partition to
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ensure no spill-over light interacted with the control sam-
ple. The lid of the control cell plate was also removed to
ensure interactions with the atmosphere within the incu-
bator did not account for the changes seen. In initial
experiments, cells were exposed for 5 minutes, 15 minutes
or 6 hours, followed by incubation for 24 hours before
being prepared for flow cytometric analysis of cell surface
marker expression. The cells used for analysis of gene
expression were exposed to PL for 6 hours, immediately
snap frozen, and their RNA isolated prior to their
preparation for PCR gene array analysis. All analysis was
performed in triplicate as technical replicates.
2.3 | Flow cytometry
The cells were labeled for flow cytometry according to
manufacturer's instructions, and standard protocols. All
antibodies were titrated prior to the experiment to ensure
optimal working concentrations. Briefly, cells were plated
FIGURE 1 A, Summary
figure of different physical
properties of phototherapeutic
light. B, Summary of the process of
light polarization
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in a 96-well U-bottom plate and treated with FcR block-
ing reagent for 10 minutes at room temperature. The
cells were then incubated with their specific conjugated
antibody (CD86-Alexa-Fluor 488, Major Histocompatibil-
ity Complex Class [MHC] I, II-BV510, CD206-PE-Cy7,
CB11b-PE or CD14-BV421) for 45 minutes in the dark at
4C at a predetermined concentration. Other antibodies
against CD40, CD83 and CD209 were negative on this
cell line and were subsequently not used. Cells were
transported after labeling in the dark on ice prior to anal-
ysis. Analysis was performed with a BD FACSCanto II
flow cytometer, with three lasers (violet - 405 nm, blue –
488 nm and red – 633 nm). Isotype controls were used to
control for background fluorescence. All conjugated anti-
bodies were sourced from BD Biosciences (San Jose, Cali-
fornia) to ensure compatibility with the flow cytometer
used. Analysis of data was done with BD FACSDiva soft-
ware (Version 3.0). The monocyte population was gated
on forward and side scatter plots and analyzed for fluo-
rescence intensity against unilluminated control cells.
Results are reported as flow cytometric dot plots with gat-
ing strategies, overlay histograms of control and treated
cells, and median fluorescence intensity, as rec-
ommended by the International Society for the Advance-
ment of Cytometry data standards task force [27].
2.4 | Gene arrays
All reagents and consumables used in RNA extraction,
cDNA synthesis and gene expression analysis were acquired
from QIAGEN (Hilden, Germany). The array used was the
RT2 Profiler PCR array “Human Innate and Adaptive
Immune Responses” which analyses 84 genes related to
immune and inflammatory responses, including key cyto-
kines, chemokines and immune active surface membrane
receptors. RNA quality and concentration were assessed via
Agilent 2100 Bioanalyzer, Qubit fluorimeter (Invitrogen) and
spectrophotometer (DeNovix). RNA extraction was
performed using the RNeasy Mini kit according to the man-
ufacturer's instructions. Briefly, cells were lysed in RLT
buffer containing β-mercaptoethanol (10 μL/mL) and
centrifuged through a QIAshredder column. Lysates were
passed through RNeasy spin columns, treated on-column
with DNase, following which the RNA was collected in
RNase free water for preparation of cDNA. cDNA was pre-
pared in a thermal cycler using the Qiagen RT2 First Strand
kit. Briefly, RNA (500 ng) was incubated at 42C for
2 minutes in the presence of GE buffer (containing DNase)
to eliminate any remaining genomic DNA, before being
immediately transferred to ice. cDNA was reverse tran-
scribed for 15 minutes at 42C, and at 92C for 3 minutes to
terminate the reactions. cDNA was then added to the RT2
SYBR green qPCR master mix and dispensed to the 96-well
gene array plate as per manufacturer's instructions. The gene
array was run in Biorad CFX96 real-time PCR cycler with an
initial denaturation step of 10 minutes at 95C, followed by
40 cycles of 15 seconds at 95C and 1 minute at 60C. Once
the RT-PCR was complete, melt curve analysis was per-
formed to ensure the presence of a single PCR product for
each gene. Gene array data were analyzed using CFX Mae-
stro (BioRad). An unpaired t test was used to compare
groups; a P value ≤.05 and a 2-fold change in expression
were set as thresholds for significance. Genes were excluded
from further analysis if the crossing point (Cq) value was
greater than 34 and/or a unique melting temperature was
not observed.
3 | RESULTS
3.1 | Polarized light decreases the
expression of cell surface markers related
to inflammation
Gating used for analysis was performed against appro-
priate isotype controls to account for background fluo-
rescence. Example gating strategy is shown in Figure 3.
FIGURE 2 Experimental set up in a standard cell culture incubator
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No change to cell surface marker expression was seen
after 5 or 30 minutes of PL exposure. The cell surface
marker expression change after 6 hours exposure to PL
is shown (Figure 4). Six hours of exposure to PL caused
a mean decrease in the median fluorescence intensity of
23% for CD11b, 39% for CD14, 27% in MHC I and 35%
in MHC II, though MHC II expression was low at base-
line (Figure 4). Conversely, there was a mean increase
in the median fluorescence of 20% in CD86. There were
no consistent changes seen in CD206 expression.
3.2 | Polarized light decreases genes
related to inflammation
All experimental and control samples passed the inbuilt
quality control measures in the gene array. Normaliza-
tion was performed against the two most stable house-
keeping genes—GAPDH and RPLP0. Cutoff points were
set at 2-fold up or downregulation, and P values calcu-
lated with significance level set at P < .05. The results are
summarized in Figures 5 and 6. Figure 5 shows genes
with significant change in regulation, and more than
2-fold regulation, and the total changes for all expressed
FIGURE 4 Changes in cell surface marker expression as assessed by flow cytometry following 6 hours exposure to polarized light
therapy. Live cells were gated on FSC vs SSC profile and isotype control antibodies were used as background control. Shown are values
above the background isotype controls. Experiments were performed in triplicate; representative samples are displayed in dot plots and
histograms. MFI, median fluorescence intensity
FIGURE 3 Example gating strategy. Left-hand panel, doublet discrimination strategy; middle panel, monocytes gated using size and
density; right-hand panel, fluorescence intensity of the given antibody with quadrants for visual inspection. FSC-A, forward scatter area;
FFC-H, forward scatter height; SSC-A: Side scatter area
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FIGURE 6 Bar graphs of relative normalized fold regulation of significant genes compared to reference point of 1.0. *P < .05;
**P < .01; ***P < 0.001
FIGURE 5 Gene expression changes following 6 hours of PLT. Top Left, fold regulation andsignificance of genes; top right, scatter plot
of fold regulation; bottom, clustered heat map. Experiments were repeated three times and mean of three repeats are shown
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genes are presented as a scatter plot and heat map.
Figure 6 shows the specific change in expression of the
six genes that reached greater than 2-fold up- or down-
regulation, and statistical significance. Six hours of PLT
caused upregulation of NFKBIA and TLR9, and down-
regulation of IL1B, CCL2, NLRP3 and NOD1. NFKBIA
is a key inflammatory inhibitor of cytokine production,
and TLR9 codes for the production of the toll-like recep-
tor 9, a key membrane receptor involved in pathogen
recognition and immune activation. IL1B and CCL2 are
important cytokines, while NLRP3 and NOD1 are mem-
brane receptors involved in inflammatory signaling. All
other genes assessed in the array did not reach the signifi-
cance and fold regulation cutoffs.
4 | DISCUSSION
This study demonstrates that PLT can exert a measurable
effect on the human immune system, giving much
needed mechanistic evidence for its clinical effects. While
phototherapies such as low-level laser have been previ-
ously shown to have a suppressive effect on inflammation
and immune response [2], very limited evidence exists
investigating whether PLT has the same capacity. The
results of this study demonstrate changes in gene expres-
sion and cell surface marker expression in differentiated
U937 cells following 6 hours exposure of PL. This sug-
gests that PLT has the capacity to cause modulation of
the behavior of activated monocytes in vitro. This could
aid in explaining the demonstrated effects of PLT in
improving wound healing and decreasing pain and
inflammation in vivo.
The cell surface markers studied here are known to
be involved in a range of processes vital to the immune
and inflammatory response, including recognition of self,
T cell activation, recognition and phagocytosis of patho-
gens and immune cell infiltration and accumulation. It is
difficult to predict how the observed changes demon-
strated in this research translate into the infinitely more
complex cellular environment surrounding an inflamma-
tory or healing process, however possible in vivo effects
may be inferred. The MHC I and MHC II receptors are
involved in antigen presentation [28] and CD11b receptor
in inflammatory cell accumulation [29] and the CD14
receptor is associated with the detection and phagocytosis
of bacterial lipopolysaccharides, and other proteinaceous
debris by macrophages [30]. Their suppression may sig-
nify a decrease in the inflammatory activity of these cells
and have the net effect of dampening the intensity and
hastening the resolution of inflammation in vivo. Similar
changes in immune cell marker expression have been
shown in other cell types following exposure to LLLT,
suggesting the possibility of common mechanisms for the
actions of phototherapies [31, 32]. CD86 has been shown
to play an important role in the amplification and main-
tenance of an inflammatory state in vivo [33, 34]. This
could result in faster clearance of debris and pathogens
and a hastening of the resolution of the inflammatory
response, leading to enhanced healing times, correlating
with the observed clinical effects of PLT.
While the reduction in cell surface markers suggests a
functional immunomodulatory effect, changes in gene
expression provide a mechanistic insight into the cellular
response to PLT. The downregulation of IL1B, CCL2,
NLRP3 and NOD1 suggests a dampening of the immune
and inflammatory response. These genes and their associ-
ated products are implicated in lymphocyte differentia-
tion and proliferation, inflammasome activation [35],
systemic inflammation [36], immune cell migration and
accumulation [37], antigen recognition [38, 39] and
phagocyte activity [39]. Others have described decreases
in IL1B in murine wound models and aortic smooth mus-
cle cells following exposure to LLLT [40, 41] and LED
therapy [42]. Additionally, LLLT has been shown to
increase or decrease the expression of CCL2 at different
intensities in the THP-1 monocyte cell line, suggesting a
dose-dependent effect [43]. The findings in this study pro-
vide a theoretical mechanism for their in vivo findings.
Decreasing the expression of these genes in activated
monocyte/macrophage cells is likely to cause a functional
reduction in inflammation. The observed increase in
NFKBIA fits within the picture of immune suppression,
as this gene has been shown to modulate and decrease
the effects of malignant [44], inflammatory [45] and
auto-immune disease [46]. The outcome of the PL medi-
ated increase in TLR9 expression might play is less clear.
It is involved in the recognition and binding of bacterial
and viral DNA and has been associated with auto-
immune disease and inflammation [47], but how an
upregulation of these processes might exert an anti-
inflammatory or increased healing state is unclear.
While this research provides proof of concept for a
physiological mechanism by which PLT may exert its clin-
ical effects, many questions remain. Firstly, whilst mono-
cyte/macrophage cells are important contributors to
inflammation and healing processes, there are a host of
other cells involved in the natural setting. Further studies
to evaluate whether PLT exerts a change on other impor-
tant immune, connective tissues and stem cells are neces-
sary to give a more integrated picture of the effects of PLT
on tissue healing. Additionally, while cell lines are a con-
venient and useful research tools, their behavior may not
perfectly reflect that of their in vivo counterparts. Conse-
quently, evaluation of how PLT may affect the diverse
range of native cellular interactions involved in healing
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and inflammation should be examined through animal
model research. The effect of light penetrance must also
be evaluated to identify whether the effects shown in this
study are equivalent to those that might occur in a clinical
setting where the incident light is obstructed by overlying
tissues. While PL has been shown to penetrate to a depth
of up to 5 centimeters [7], it is currently unclear if its abil-
ity to exert a physiological change is affected by distance
from the light source or the light transmitting properties
of the tissue being treated. Finally, the dose response of
PLT must be evaluated further. This study identified
6 hours of PLT as being able to generate a cellular
response, but for translation into clinical use, minimum
effective timeframes must be identified, and the effects of
repeated dosages must also be explored further.
5 | CONCLUSION
Noninvasive, nonpharmacological interventions to treat
inflammation and to assist in the process of tissue healing
have the potential to revolutionize the treatment of a
wide range of conditions. This study provides preliminary
evidence suggesting that PLT could be a candidate to fill
this gap in therapeutic approaches.
This study provides key mechanistic evidence for the
capacity of PLT to impart a physiological change. The
changes in gene and cell surface marker expression
observed after 6 hours of PLT were suggestive of immune
and inflammatory suppression, providing potential for
clinical use in a host of illnesses and injuries. These find-
ings support the reported results of PLT seen in clinical
practice, where it is used to assist in the healing of
wounds and injuries. Future research on other cell types
should be performed to establish a clear mechanism, and
dose response experiments done to identify optimal treat-
ment practices. Further, studies comparing the effect of
the individual wavelengths that make up PLT could
allow for more targeted therapeutic approaches.
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